{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T11:53:37Z","timestamp":1781783617363,"version":"3.54.5"},"reference-count":92,"publisher":"Informa UK Limited","issue":"9","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Pharmacotherapy"],"published-print":{"date-parts":[[2026,6,13]]},"DOI":"10.1080\/14656566.2026.2685830","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T11:44:30Z","timestamp":1780573470000},"page":"797-807","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Injectable long-acting pre-exposure prophylaxis for HIV prevention: advancements and future directions in pharmacotherapy"],"prefix":"10.1080","volume":"27","author":[{"given":"Angelo Roberto","family":"Raccagni","sequence":"first","affiliation":[{"name":"Vita-Salute San Raffaele University","place":["Milan, Italy"]},{"name":"IRCCS San Raffaele Scientific Institute","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Castagna","sequence":"additional","affiliation":[{"name":"Vita-Salute San Raffaele University","place":["Milan, Italy"]},{"name":"IRCCS San Raffaele Scientific Institute","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Nozza","sequence":"additional","affiliation":[{"name":"Vita-Salute San Raffaele University","place":["Milan, Italy"]},{"name":"IRCCS San Raffaele Scientific Institute","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,6,6]]},"reference":[{"key":"e_1_3_4_3_1","unstructured":"UNAIDS. Global HIV & AIDS statistics. Available from: https:\/\/www.unaids.org\/en\/resources\/fact-sheet"},{"key":"e_1_3_4_4_1","volume-title":"Guidelines on long-acting injectable cabotegravir for HIV prevention","author":"World Health Organization","year":"2022","unstructured":"World Health Organization. Guidelines on long-acting injectable cabotegravir for HIV prevention. Geneva: WHO; 2022."},{"key":"e_1_3_4_5_1","volume-title":"Guideline on long-acting injectable lenacapavir for HIV prevention and HIV testing strategies for long-acting PrEP","author":"World Health Organization","year":"2025","unstructured":"World Health Organization. Guideline on long-acting injectable lenacapavir for HIV prevention and HIV testing strategies for long-acting PrEP. Geneva: WHO; 2025."},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1011205"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1108524"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(22)00133-3"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2023.100738"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-2667(22)00106-2"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(23)00080-2"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(23)00171-6"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2019.24.41.1900598"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaf539"},{"issue":"1","key":"e_1_3_4_15_1","first-page":"37","article-title":"Brief report: gaps in HIV preexposure prophylaxis acceptance: findings from an outpatient HIV testing service in Italy","volume":"98","author":"Raccagni AR","year":"2025","unstructured":"Raccagni AR, Passini F, Diotallevi S, et al. Brief report: gaps in HIV preexposure prophylaxis acceptance: findings from an outpatient HIV testing service in Italy. J Acquir Immune Defic Syndr. 2025;98(1):37\u201340.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae531"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2101016"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00538-4"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiab152"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)00983-3"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(20)30106-5"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002690"},{"key":"e_1_3_4_23_1","volume-title":"Apretude (cabotegravir) injection: prescribing information","author":"U.S. Food and Drug Administration","year":"2021","unstructured":"U.S. Food and Drug Administration. Apretude (cabotegravir) injection: prescribing information. 2021. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/215499s000lbl.pdf"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7435a1"},{"key":"e_1_3_4_25_1","volume-title":"Yeztugo (lenacapavir) tablets and injection: prescribing information","author":"U.S. Food and Drug Administration","year":"2025","unstructured":"U.S. Food and Drug Administration. Yeztugo (lenacapavir) tablets and injection: prescribing information. 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/220020s000lbl.pdf"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-022-03816-0"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0000000000000597"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15439"},{"key":"e_1_3_4_29_1","first-page":"Abstract LB19","volume-title":"Presented at IAS","author":"Moore M","year":"2025","unstructured":"Moore M, Stansfield S, Donnell DJ, et al. Model-based efficacy of long-acting cabotegravir by time since last injection among cisgender men and transgender women enrolled in HPTN 083. In: Presented at IAS; Kigali, Rwanda; 2025. p. Abstract LB19."},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiaf561"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaf285"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0000000000000919"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.26493"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.2196\/60961"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.2196\/44961"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2025.30.39.2500739"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1097\/OLQ.0000000000002272"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.70162"},{"key":"e_1_3_4_39_1","first-page":"Abstract 1058","volume-title":"Presented at CROI","author":"Mazzotta V","year":"2026","unstructured":"Mazzotta V, Nozza S, Leone S, et al. Coverage and discontinuation of long-acting cabotegravir vs oral PrEP in the Italian PrIDE cohort. In: Presented at CROI; Denver (CO); 2026. p. Abstract 1058."},{"key":"e_1_3_4_40_1","first-page":"Abstract 978","volume-title":"Presented at CROI","author":"Preer B","year":"2026","unstructured":"Preer B, Anzalone J, Patel R, et al. Prescriptions for oral vs injectable HIV preexposure prophylaxis, 2012\u20132025. In: Presented at CROI; Denver (CO); 2026. p. Abstract 978."},{"key":"e_1_3_4_41_1","first-page":"Abstract 979","volume-title":"Presented at CROI","author":"Brunet L","year":"2026","unstructured":"Brunet L, Hsu R, Mills A, et al. Cabotegravir LA for PrEP: progress in HIV prevention from 3 years of OPERA data. In: Presented at CROI; Denver (CO); 2026. p. Abstract 979."},{"key":"e_1_3_4_42_1","first-page":"Abstract 981","volume-title":"Presented at CROI","author":"McEwen I","year":"2026","unstructured":"McEwen I, Sridhar G, Elion R, et al. Long-term use, HIV testing & effectiveness in individuals on CAB LA PrEP in the trio Health cohort. In: Presented at CROI; Denver (CO); 2026. p. Abstract 981."},{"key":"e_1_3_4_43_1","first-page":"Abstract OAC040","volume-title":"Presented at IAS","author":"Mukherjee T","year":"2025","unstructured":"Mukherjee T, Kimmel A, Martindale L, et al. Lessons learned from the introduction of PEPFAR supported long-acting injectable cabotegravir (CAB-LA) in shaping global prevention efforts. In: Presented at IAS; Kigali, Rwanda; 2025. p. Abstract OAC0402."},{"key":"e_1_3_4_44_1","first-page":"Abstract TUPEE1","volume-title":"Presented at IAS","author":"Kawanga L","year":"2025","unstructured":"Kawanga L, Ndhlovu S, Mwamba D, et al. Survival of individuals on long-acting cabotegravir for HIV pre-exposure prophylaxis and associated discontinuation factors in Zambia: a 10 months retrospective cohort analysis. In: Presented at IAS; Kigali, Rwanda; 2025. p. Abstract TUPEE129."},{"key":"e_1_3_4_45_1","first-page":"Abstract LB48","volume-title":"Presented at IAS","author":"Stoebenau K","year":"2025","unstructured":"Stoebenau K, Mwale M, Muchanga G, et al. \u201cYou get the injection and it\u2018s done\u201d: qualitative findings from the first real-world implementation of long-acting cabotegravir for HIV prevention among adolescent girls and young women in Zambia. In: Presented at IAS; Kigali, Rwanda; 2025. p. Abstract LB48."},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.26491"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaf173"},{"key":"e_1_3_4_48_1","first-page":"Abstract 187","volume-title":"Presented at CROI","author":"Hoege D","year":"2026","unstructured":"Hoege D, Ozituosauka W, Schluth C, et al. Early findings from cabotegravir injectable HIV PrEP rollout in Malawi: uptake and continuation. In: Presented at CROI; Denver (CO); 2026. p. Abstract 187."},{"key":"e_1_3_4_49_1","first-page":"Abstract 983","volume-title":"Presented at CROI","author":"Macul H","year":"2026","unstructured":"Macul H, El-Sadr W, Couto A, et al. Long-acting cabotegravir PrEP among adolescent girls and young women: pilot results, Mozambique 2025. In: Presented at CROI; Denver (CO); 2026. p. Abstract 983."},{"key":"e_1_3_4_50_1","first-page":"Abstract 1075","volume-title":"Presented at CROI","author":"Springer S","year":"2026","unstructured":"Springer S, Di Paola A, Frank C, et al. Closing PrEP access gaps: results from the first legalized mobile retail pharmacy clinic. In: Presented at CROI; Denver (CO); 2026. p. Abstract 1075."},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.1128\/cmr.00395-25"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2024.2415295"},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.3390\/v14061202"},{"issue":"1","key":"e_1_3_4_54_1","first-page":"ofaf695","article-title":"Favorable adherence and safety of twice-yearly subcutaneous lenacapavir for PrEP among PURPOSE 2 participants who used substances","volume":"13","author":"Agwu JC","year":"2026","unstructured":"Agwu JC, Buchbinder SP, Blumenthal J, et al. Favorable adherence and safety of twice-yearly subcutaneous lenacapavir for PrEP among PURPOSE 2 participants who used substances. Open Forum Infect Dis. 2026;13(Suppl 1):ofaf695.","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"e_1_3_4_55_1","article-title":"No clinically significant drug\u2013drug interactions with Co-administration of feminizing or masculinizing hormone therapy and twice-yearly lenacapavir PrEP in gender-diverse persons","volume":"13","author":"Blumenthal J","year":"2026","unstructured":"Blumenthal J, Acevedo-Quinones M, Phanuphak N, et al. No clinically significant drug\u2013drug interactions with Co-administration of feminizing or masculinizing hormone therapy and twice-yearly lenacapavir PrEP in gender-diverse persons. Open Forum Infect Dis. 2026;13(Suppl 1):ofaf695.525.","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"e_1_3_4_56_1","article-title":"No clinically significant drug-drug interactions between lenacapavir and hormonal contraceptives in PURPOSE 1","volume":"13","author":"Potloane D","year":"2026","unstructured":"Potloane D, Louw CE, Kigozi G, et al. No clinically significant drug-drug interactions between lenacapavir and hormonal contraceptives in PURPOSE 1. Open Forum Infect Dis. 2026;13(Suppl 1):ofaf695.519.","journal-title":"Open Forum Infect Dis"},{"key":"e_1_3_4_57_1","volume-title":"Presented at EACS","author":"Avihingsanon A","year":"2025","unstructured":"Avihingsanon A, Ogbuagu O, Frank I, et al. Commonly prescribed concomitant medications and clinical safety findings with lenacapavir for pre-exposure prophylaxis in PURPOSE 2. In: Presented at EACS; Paris, France; 2025. p. Abstract MeP16.1."},{"key":"e_1_3_4_58_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2407001"},{"key":"e_1_3_4_59_1","first-page":"Abstract 128","volume-title":"Presented at CROI","author":"Ndlovu N","year":"2026","unstructured":"Ndlovu N, Malahleha M, Singh Y, et al. Twice-yearly subcutaneous lenacapavir for PrEP: updated HIV-1 incidence and safety data in PURPOSE 1. In: Presented at CROI; Denver (CO); 2026. p. Abstract 128."},{"key":"e_1_3_4_60_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2411858"},{"key":"e_1_3_4_61_1","doi-asserted-by":"publisher","DOI":"10.1128\/mbio.03613-24"},{"key":"e_1_3_4_62_1","first-page":"Abstract 130","volume-title":"Presented at CROI","author":"Cox S","year":"2026","unstructured":"Cox S, Andreatta K, Hendricks M, et al. Resistance analyses of the PURPOSE studies through the end of the randomized blinded phase. In: Presented at CROI; Denver (CO); 2026. p. Abstract 130."},{"key":"e_1_3_4_63_1","first-page":"Abstract 129","volume-title":"Presented at CROI","author":"Cantos Lucio V","year":"2026","unstructured":"Cantos Lucio V, Mngadi K, Supparatpinyo K, et al. Lenacapavir for PrEP: HIV-1 incidence and safety from PURPOSE 2 at end of randomized blinded phase. In: Presented at CROI; Denver (CO); 2026. p. Abstract 129."},{"key":"e_1_3_4_64_1","first-page":"Abstract OAC050","volume-title":"Presented at IAS","author":"Gill K","year":"2025","unstructured":"Gill K, Karim A, Anugulruengkitt S, et al. Efficacy, safety, and pharmacokinetics of twice-yearly subcutaneous lenacapavir for PrEP among adolescents and young people in the phase 3 trials PURPOSE 1 and PURPOSE 2. In: Presented at IAS; Kigali, Rwanda; 2025. p. Abstract OAC0503."},{"key":"e_1_3_4_65_1","first-page":"Abstract OAC050","volume-title":"Presented at IAS","author":"Bekker LG","year":"2025","unstructured":"Bekker LG, Moodley D, Harkoo I, et al. Inclusion of pregnant and lactating people in the PURPOSE 1 study: efficacy, safety, and pharmacokinetics. In: Presented at IAS; Kigali, Rwanda; 2025. p. Abstract OAC0504."},{"key":"e_1_3_4_66_1","first-page":"Abstract OAC050","volume-title":"Presented at IAS","author":"Mngadi K","year":"2025","unstructured":"Mngadi K, Phanuphak N, Hinojosa Preference JC, et al. For twice-yearly injections vs daily oral pills for HIV PrEP in cisgender men, transgender women, transgender men, and gender nonbinary people enrolled in PURPOSE 2. In: Presented at IAS; Kigali, Rwanda; 2025. p. Abstract OAC0502."},{"key":"e_1_3_4_67_1","first-page":"Abstract TUPEC0","volume-title":"Presented at IAS","author":"Mansoor LE","year":"2025","unstructured":"Mansoor LE, Lebina L, Makhoba P, et al. Predictors of HIV pre-exposure prophylaxis preferences using the Health belief model: twice-yearly subcutaneous lenacapavir versus daily pills in the PURPOSE 1 trial. In: Presented at IAS; Kigali, Rwanda; 2025. p. Abstract TUPEC057."},{"key":"e_1_3_4_68_1","first-page":"Abstract 1062","volume-title":"Presented at CROI","author":"Tao L","year":"2026","unstructured":"Tao L, Yang J, Nguyen A, et al. Real-world medication use and potential interactions with lenacapavir for HIV PrEP. In: Presented at CROI; Denver (CO); 2026. p. Abstract 1062."},{"key":"e_1_3_4_69_1","volume-title":"Presented at EACS","author":"Ogbuagu O","year":"2025","unstructured":"Ogbuagu O, Mounzer K, Diaz RS, et al. Annual persistence to twice-yearly lenacapavir versus daily oral F\/TDF for PrEP in the PURPOSE 2 trial. Presented at EACS, Paris, France; 2025. p. Abstract PS08.5."},{"key":"e_1_3_4_70_1","first-page":"Abstract EP0725","volume-title":"Presented at IAS","author":"Nyamaizi AM","year":"2025","unstructured":"Nyamaizi AM, Hawley I, Isidoro L, et al. Exploratory qualitative analysis of the acceptability of HIV prevention methods among pregnant and lactating women interviewed during the randomized blinded phase of PURPOSE 1. In: Presented at IAS; Kigali, Rwanda; 2025. p. Abstract EP0725."},{"key":"e_1_3_4_71_1","volume-title":"Presented at EACS","author":"Zeggagh J","year":"2025","unstructured":"Zeggagh J, Tassi MF, Schwerer CA, et al. The potential impact of twice-yearly injectable lenacapavir among cisgender gay, bisexual, and other men who have sex with men (GBMSM) and other priority HIV prevention populations (transgender people and highly exposed heterosexual people) in France. In: Presented at EACS; Paris, France; 2025. p. Abstract MeP16.2."},{"key":"e_1_3_4_72_1","doi-asserted-by":"publisher","DOI":"10.1177\/23259582251390622"},{"key":"e_1_3_4_73_1","volume-title":"Presented at EACS","author":"Molina JM","year":"2025","unstructured":"Molina JM, Clarke A, Lacombe K, et al. Recruitment of disproportionately affected populations in the PURPOSE 5 study evaluating lenacapavir for PrEP in France and the Uk. In: Presented at EACS; Paris, France; 2025. p. Abstract PS02.4."},{"key":"e_1_3_4_74_1","first-page":"Abstract EPLB00","volume-title":"Presented at IAS","author":"Hawkins N","year":"2025","unstructured":"Hawkins N, Thompson J, Grove R, et al. Indirect treatment comparison of the efficacy of cabotegravir and lenacapavir for HIV pre-exposure prophylaxis (PrEP) versus no PrEP. In: Presented at IAS; Kigali, Rwanda; 2025. p. Abstract EPLB005."},{"key":"e_1_3_4_75_1","first-page":"Abstract 988","volume-title":"Presented at CROI","author":"Fox D","year":"2026","unstructured":"Fox D, Boles J, Vutikullird A, et al. Injection-site reactions more common and bothersome with single doses of lenacapavir vs Cabotegravir. In: Presented at CROI; Denver (CO); 2026. p. Abstract 988."},{"key":"e_1_3_4_76_1","unstructured":"ClinicalTrials.gov. Study of lenacapavir and emtricitabine\/tenofovir disoproxil fumarate (F\/TDF) for prevention of HIV in people who inject drugs (HPTN 103) (PURPOSE 4). Identifier: NCT06101342."},{"key":"e_1_3_4_77_1","unstructured":"ClinicalTrials.gov. Study of lenacapavir and emtricitabine\/tenofovir disoproxil fumarate (F\/TDF) in prevention of HIV in cisgender women in the United States (HPTN 102) (PURPOSE 3). Identifier: NCT06101329."},{"key":"e_1_3_4_78_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15051487"},{"key":"e_1_3_4_79_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2023.115009"},{"issue":"2","key":"e_1_3_4_80_1","first-page":"508","article-title":"CROI 2025: global epidemiology and prevention of HIV and other sexually transmitted diseases","volume":"33","author":"Buchbinder SP","year":"2025","unstructured":"Buchbinder SP, Liu AY. CROI 2025: global epidemiology and prevention of HIV and other sexually transmitted diseases. Top Antivir Med. 2025;33(2):508\u2013535. PMID: 40472386.","journal-title":"Top Antivir Med"},{"key":"e_1_3_4_81_1","unstructured":"ClinicalTrials.gov. Study of lenacapavir taken twice a year for HIV pre-exposure prophylaxis (PrEP) (PURPOSE 5). Identifier: NCT06513312."},{"key":"e_1_3_4_82_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)00405-2"},{"key":"e_1_3_4_83_1","unstructured":"ClinicalTrials.gov. A clinical study of MK-8527 to prevent human immunodeficiency virus type 1 (HIV-1) (MK-8527\u2013011). Identifier: NCT07044297."},{"key":"e_1_3_4_84_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiaf610"},{"key":"e_1_3_4_85_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.3003308"},{"key":"e_1_3_4_86_1","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.70001"},{"key":"e_1_3_4_87_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11904-025-00744-1"},{"key":"e_1_3_4_88_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(24)00308-4"},{"key":"e_1_3_4_89_1","doi-asserted-by":"publisher","DOI":"10.3389\/frph.2023.1254953"},{"key":"e_1_3_4_90_1","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.25064"},{"key":"e_1_3_4_91_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2025.114575"},{"key":"e_1_3_4_92_1","doi-asserted-by":"publisher","DOI":"10.3390\/v17091192"},{"key":"e_1_3_4_93_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2025.114166"},{"key":"e_1_3_4_94_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgph.0005028"}],"container-title":["Expert Opinion on Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14656566.2026.2685830","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T11:27:30Z","timestamp":1781782050000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14656566.2026.2685830"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,6]]},"references-count":92,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,6,13]]}},"alternative-id":["10.1080\/14656566.2026.2685830"],"URL":"https:\/\/doi.org\/10.1080\/14656566.2026.2685830","relation":{},"ISSN":["1465-6566","1744-7666"],"issn-type":[{"value":"1465-6566","type":"print"},{"value":"1744-7666","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,6]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-04-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}